EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Generation of RNA aptamers against chikungunya virus E2 envelope protein

Kaku Goto iD, Ryo Amano, Akiko Ichinose, Akiya Michishita, Michiaki Hamada, Yoshikazu Nakamura, Masaki Takahashi iD

Journal of Virology · 2025

DOI: 10.1128/jvi.02095-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Kaku Goto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Chikungunya virus, Viral Envelope Proteins, Antiviral Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST CREST, Grant-in-aid for Challenging Research (Exploratory).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleic acid aptamers are a promising drug modality, whereas the generation of virus-neutralizing aptamers has remained difficult due to the lack of a robust system for targeting the viral particles of interest. Here, we took advantage of our latest platform technology of Systematic Evolution of Ligands by EXponential enrichment (SELEX) with virus-like particles (VLPs) and targeted chikungunya virus (CHIKV) as a model, the pathogenic reemerging virus with an unmet need for control. The identified aptamer against CHIKV-VLPs, Apt#1, and its truncated derivatives showed neutralizing activity with nanomolar IC50 values in a cell-based assay system using a pseudoviral particle of CHIKV (CHIKVpp). An antiviral-based chemical genetics approach revealed significant competition of Apt#1 with suramin, a reported interactant with domain A of the E2 envelope protein (E2DA), in both CHIKVpp and surface plasmon resonance (SPR) analyses, predicting E2DA to be the Apt#1 interface. In addition, Apt#1 interfered with the attachment of CHIKVpp, collectively suggesting its property as an attachment inhibitor via E2DA of CHIKV. Thus, the generation of the VLP-targeted aptamers proved to contribute to anti-CHIKV strategies and confirmed the utility of the platform as a novel and viable option for the development of neutralizing agents against viral particles of interest. IMPORTANCE Our latest SELEX technology using VLPs has generated aptamers that bind the native conformation of the incorporated envelope protein and achieve the virus binding and neutralizing effects. Indeed, the aptamer-probed target E2DA is a representative neutralization site on the surface of the viral particle, validating the utility of the VLP-driven procedure. Simultaneously, the enhanced antiviral effects of the aptamer in combination with approved drugs using the CHIKVpp assay with human cells indicated potential therapeutic strategies that are expected to help address unmet needs in CHIKV control. The robust affinity of the aptamer to viral particles demonstrated by SPR analysis can also lead to conjugates with antivirals as guiding molecules and aptasensors for diagnostic tools. Overall, our VLP-based method provided anti-CHIKV as well as a versatile platform applicable to other emerging and reemerging viruses, in preparation for outbreaks with the need for rapid development of antiviral strategies as next-generation theranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideChikungunya virusViral Envelope ProteinsAntiviral AgentsSELEX Aptamer TechniqueHumansAnimalsChikungunya FeverSurface Plasmon ResonanceSuraminVirus AttachmentCell LineVero Cells

Stichwörter der Autor:innen

CHIKVaptamerneutralization

Substanzen

Aptamers, NucleotideViral Envelope ProteinsAntiviral AgentsSuramin

Autor:innen und Institutionen

  • Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
  • RIBOMIC Inc., Tokyo, Japan.

ORCID-Profile: Kaku Goto, Masaki Takahashi

Förderung

  • JST CREST
  • Grant-in-aid for Challenging Research (Exploratory)

Zitieren

APA

Goto, K., Amano, R., Ichinose, A., Michishita, A., Hamada, M., Nakamura, Y., & Takahashi, M. (2025). Generation of RNA aptamers against chikungunya virus E2 envelope protein. Journal of Virology. https://doi.org/10.1128/jvi.02095-24

Vancouver

Goto K, Amano R, Ichinose A, Michishita A, Hamada M, Nakamura Y, et al. Generation of RNA aptamers against chikungunya virus E2 envelope protein. Journal of Virology. 2025. doi:10.1128/jvi.02095-24

BibTeX
@article{Goto2025,
  author = {Goto, Kaku and Amano, Ryo and Ichinose, Akiko and Michishita, Akiya and Hamada, Michiaki and Nakamura, Yoshikazu and Takahashi, Masaki},
  title = {Generation of RNA aptamers against chikungunya virus E2 envelope protein},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.02095-24}
}
Kostenlos starten →